Hepatitis C Virus Infection: Looking Beyond the Interferon Alfa Era
Tuesday, September 24, 2013
8:00 AM to 4:00 PM
Assessment of Needs
IAS–USA has expanded its mission to include activities that relate to the management of viral infections other than HIV. The full-day course will focus on hepatitis C virus (HCV) infection. Rapid advances in treatment are anticipated with the introduction of direct-acting antivirals (DAAs) to the HCV treatment paradigm. With the projected large increase in the number of patients who will require HCV treatment in the near future, clinicians who are experts in the complexities of antiretroviral management are uniquely well positioned to join our hepatology and gastroenterology colleagues in providing care for these patients, in what promises to be an exciting new era in HCV care.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This course is designed for physicians and other health care practitioners who are experienced in the principles of complex chemotherapy (eg, antiretroviral therapy) and are actively treating or will be treating patients with HCV infection.
This activity is also relevant for other practitioners including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Upon completion of the course, participants will be able to:
- Identify patients who should begin therapy
- Develop effective treatment regimens
- Describe the current data on available hepatitis C virus (HCV) protease inhibitor-based treatments, the emergence of resistance, and describe investigational direct-acting antivirals and interferon alfa regimens
- Describe the effects of HCV on the liver and be able to describe effective approaches for treating end-stage liver disease
- Describe drug-drug interactions, especially in HIV/HCV coinfected patients on antiretroviral therapy
- Manage the adverse effects of HCV treatments
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Family Physicians Credit
This live activity, Hepatitis C Virus Infection: Looking Beyond the Interferon Alfa Era, with a beginning date of September 24, 2013, has been reviewed and is acceptable for up to 7.25 Prescribed credits by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved provider of continuing education in nursing by ASNA, an accredited provider by the ANCC/Commission on Accreditation. Provider # 5-115. This program is approved for 6.75 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 6.75 hours (0.675 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE # 0761-9999-13-316-L01-P
This activity is funded through independent, educational grants at a national level from commercial organizations that are committed to supporting high-quality continuing medical education (CME). This activity is part of a national effort that includes this and other live CME courses, live course webcasts, Cases on the Web, and Topics in Antiviral Medicine.™ In the interest of an objective, unbiased, balanced, and scientifically rigorous program, the IAS–USA seeks and pools funding from companies with competing products to support the program. These companies have no input into or control over the program content or the selection of faculty. We gratefully acknowledge the support of the companies listed below.
Gilead Sciences, Inc
Merck & Co, Inc
Vertex Pharmaceuticals, Inc